ABOUT MEDISPEC

With more than 30 years of experience and expertise in shockwave therapy solutions, Medispec continuously introduces competitive systems and technological breakthroughs to the market. The company specializes in shockwave-based systems for urology, cardiovascular and orthopedics applications. Medispec services clinics, medical centers and hospitals in over 80 countries worldwide. All of the company's systems offer modular design, versatility, ease of use and high degree of mobility, for delivering innovative technology in a fast and efficient manner. All Medispec products comply with FDA* and CE regulations.



OR-5-X500 G

* Data subject to change without notice

MEDISPEC

203 Perry Parkway, Suite #6, Gaithersburg, MD 20877, USA
Tel: +1 (301) 944-1575 | Fax: +1 (301) 972-6098
E-mail: marketing@medispec.com
www.medispec.com

* Excluding Thermaspec & Cardiospec

MEDISPEC







ED1000™

EDSWT™

ERECTILE DYSFUNCTION SHOCK WAVE THERAPY

New Hope for Men who Suffer from ED

GROUNDBREAKING TECHNOLOGY *Within Your Reach*

ED1000™

EDSWT™

WHAT IS EDSWT?

Erectile Dysfunction Shock Wave Therapy is an innovative approach to vasculogenic ED, delivered by Medispec's ED1000, a device that uses advanced acoustics technology.
This technology has proven to be affective in cardiology, with recent success in reversible ischemic tissues of the heart. EDSWT utilizes low-intensity extracorporeal shock waves, focusing on blood vessels and encouraging neovascularization in the penis shaft and crus. The low-intensity shock waves help relieve vascular deficiency, a common cause of erectile dysfunction.

EDSWT: NEW EFFECTIVENESS FOR MORE PATIENTS

Vasculogenic and diabetic ED patients will benefit from EDSWT – those who are responsive to PDE5 inhibitors as well as those who are unresponsive. For the latter, which includes a substantial number of severe ED patients, the only solution to date are vacuum pumps, injections and perhaps implants. EDSWT therapy brings hope to those patients, by allowing more than 70% of them to become responsive to PDE5 inhibitors. As "end-stage" ED patients, they will be able to enjoy normal sexual functionality.
With over 50% of men aged 40-70 suffering from ED, and even more from transient ED, Medispec's breakthrough therapeutic system can bring lasting improvement in erectile function and new sexual spontaneity to millions – painlessly, naturally and safely.



Low Intensity Shock Wave Therapy (EDSWT) was officially accepted by the European Association of Urology (EAU) as the gold standard for treatment of Erectile Dysfunction in the EAU 2013 guidelines on Male Sexual Dysfunction.
This was based on clinical trials using the Medispec's ED1000.

THE ED1000 SYSTEM BY MEDISPEC

Proven effective in clinical testing, the ED1000 is a unique mobile system that performs the EDSWT protocol in a safe, efficient manner. Vasculogenic and diabetic ED patients, who are responsive to PDE5 inhibitors as well as those who are unresponsive, can receive shock wave therapy from the ED1000 and experience improved erectile functionality. The system is available in two models, ED1000 and ED1000 Desktop.

ED1000 Desktop is designed based on Medispec's accumulated experience and expertise, enabling physicians to extend treatment availability to additional small facilities, and at home treatments. The system is modular and mobile, yet offers the same clinical advantages of the company's successful ED1000 system.


EFFECTIVE WITHOUT MEDICATION

Unlike conventional ED treatment, such as PDE5 inhibitors, EDSWT does not involve the use of any pharmaceuticals. Moreover, the shock wave treatment causes no side-effects or systemic load on other organs and healthy tissues. The non-invasive, painless EDSWT procedure is performed during a series of brief visits at the sexual health clinic, and requires no sedation or anesthesia. Discernible improvement in the erectile function of the penis can be visible within two weeks after therapy begins.
Recent clinical studies revealed that patients reported a high rate of satisfaction for more than two years after treatment – all without reliance on PDE5 inhibitors.
In clinical tests, EDSWT has shown significant long-term effectiveness. These results are confirmed by a double-blind placebo controlled study of a large group of patients.

ED1000 - Double Blind Placebo Controlled

N = 60 Median Age = 56.5

Etiology:
· Vasculogenic ED patients ·
Responders to PDE5i therapy




Vardi, Y., B. Appel, et al. "Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study." J Urol 2012; 187: 1769-1775.

ED1000 - Poorly Responders to PDE5-i

N = 29
Median Age = 62

Etiology:
· Severe vasculogenic ED patients ·
Poor responders to PDE5i therapy



Gruenwald, I., B. Appel, et al. "Low-intensity extracorporeal shock wave therapy - a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy." J Sex Med (2012); 9: 259-264.

MULTI-APPLICATIONS DEVICE

ED1000 is a multi-applications device that can be used for additional indications. Switching from treating one clinical indication to another, can be done by simply replacing the designated shock wave applicator.

Urological Indications:
· Prostatitis (CPPS)
· Peyronie's disease

Vascular Indications:
· Peripheral Artery Disease and Chronic Limb Ischemia associated with intermittent claudication
· Diabetic foot ulcers and neuropathy
· Wound healing – acute and chronic wounds

Orthopedics indications: treating inflammation and pain for various applications, including non-union fractures



BENEFITS

- Proven clinical results
- Light, compact & mobile
- Patented & exclusive technology
- Long-term effect
- Based on angiogenesis – triggers the body's natural repair mechanism
- Pain free, short treatments with no reported side - effects